

Oncology Imaging Systems Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 July 2025

Oncology Imaging Systems Limited

CONTENTS

	Page
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 10

Oncology Imaging Systems Limited

DIRECTORS AND OTHER INFORMATION

Directors	Steven Imber Joshua Imber (Appointed 1 March 2026) Jessica Fuller (Resigned 8 April 2025) Keith Rynhart (Resigned 1 March 2026)
Company Secretary	Joshua Imber (Appointed 1 March 2026) Keith Rynhart (Appointed 8 April 2025, Resigned 1 March 2026) Jessica Fuller (Resigned 8 April 2025)
Company Number	724305
Registered Office	4 Ormond Quay Upper Dublin 7 D07 PF53
Business Address	4 Fitzwilliam Terrace Strand Road Bray Co Wicklow
Accountants	FMB Advisory Limited Chartered Accountants 4 Ormond Quay Upper Dublin 7 D07PF53

Oncology Imaging Systems Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 July 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Statement of Changes in Equity and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to FMB Advisory Limited, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 July 2025."

Signed on behalf of the board

Steven Imber
Director

8 April 2026

Joshua Imber
Director

8 April 2026

Oncology Imaging Systems Limited

BALANCE SHEET

as at 31 July 2025

	Notes	2025 €	2024 €
Current Assets			
Stocks	4	19,582	19,582
Debtors	5	830	5,567
Cash and cash equivalents		420	-
		<u>20,832</u>	<u>25,149</u>
Creditors: amounts falling due within one year	6	<u>(47,760)</u>	<u>(38,244)</u>
Net Current Liabilities		<u>(26,928)</u>	<u>(13,095)</u>
Total Assets less Current Liabilities		<u>(26,928)</u>	<u>(13,095)</u>
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings		(27,028)	(13,195)
Equity attributable to owners of the company		<u>(26,928)</u>	<u>(13,095)</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Oncology Imaging Systems Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 8 April 2026 and signed on its behalf by:

Steven Imber
Director

Joshua Imber
Director

Oncology Imaging Systems Limited
STATEMENT OF CHANGES IN EQUITY

as at 31 July 2025

	Called up share capital €	Retained earnings €	Total €
At 1 August 2023	100	(8,783)	(8,683)
Loss for the financial year	-	(4,412)	(4,412)
At 31 July 2024	100	(13,195)	(13,095)
Loss for the financial year	-	(13,833)	(13,833)
At 31 July 2025	100	(27,028)	(26,928)

Oncology Imaging Systems Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

1. General Information

Oncology Imaging Systems Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 724305. The registered office of the company is 4 Ormond Quay Upper, Dublin 7, D07 PF53 and its principal place of business during the financial year was 4 Fitzwilliam Terrace, Strand Road, Bray, Co. Wicklow. The company has not commenced in formal sales trading activity in the current financial year.

The company has been engaged in preliminary pre-trading activities and the directors expect that the company will commence active trading involving the sale and distribution of oncology systems to hospital and healthcare facilities in the Republic of Ireland when customer contracts and required staffing have been put in place. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 July 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares. Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out-right short-term not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit and Loss Account.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is an approximation of the amount that the company would receive for the asset if it were to be sold at the reporting date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability.

Oncology Imaging Systems Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Related parties

For the purposes of these financial statements a party is considered to be related to the company if:

- the party has the ability, directly or indirectly, through one or more intermediaries to control the company or exercise significant influence over the company in making financial and operating policy decisions or has joint control over the company;
- the company and the party are subject to common control;
- the party is an associate of the company or forms part of a joint venture with the company;
- the party is a member of key management personnel of the company or the company's parent, or a close family member of such as an individual, or is an entity under the control, joint control or significant influence of such individuals;
- the party is a close family member of a party referred to above or is an entity under the control or significant influence of such individuals; or
- the party is a post-employment benefit plan which is for the benefit of employees of the company or of any entity that is a related party of the company.

Close family members of an individual are those family members who may be expected to influence, or be influenced by, that individual in their dealings with the company.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Employees

The company did not have any employees during the financial period other than the members of the board of directors.

Oncology Imaging Systems Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

4. Stocks	2025	2024
	€	€
Finished goods and goods for resale	<u>19,582</u>	<u>19,582</u>
The replacement cost of stock did not differ significantly from the figures shown.		
5. Debtors	2025	2024
	€	€
Taxation	<u>830</u>	<u>5,567</u>
6. Creditors	2025	2024
Amounts falling due within one year	€	€
Trade creditors	-	24,824
Amounts owed to group undertakings	44,486	10,436
Accruals	3,274	2,984
	<u>47,760</u>	<u>38,244</u>
7. Profit and loss account		
	2025	2024
	€	€
At 1 August 2024	(13,195)	(8,783)
Loss for the financial year	(13,833)	(4,412)
At 31 July 2025	<u>(27,028)</u>	<u>(13,195)</u>
8. Capital commitments		
The company had no material capital commitments at the financial year-ended 31 July 2025.		
9. Directors' remuneration	2025	2024
	€	€
Remuneration	<u>9,800</u>	<u>-</u>
10. Related party transactions		
The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.		
11. Parent company		
The company regards Oncology Imaging Systems as its parent company.		
Oncology Imaging Systems Limited is registered in the United Kingdom and director Steve Imber holds a controlling interest in its issued equity.		
12. Post-Balance Sheet Events		
The directors confirm that they remain fully satisfied that the company continues to be a going concern in conjunction with receipt of a commitment of continuing financial support from its parent undertaking which will allow it to settle its liabilities as they fall due and proceed to commence trading activities in the near future.		

Oncology Imaging Systems Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 July 2025

13. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 8 April 2026.